Rasdegafusp alfa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Rasdegafusp alfa
Accession Number
DB15185
Type
Biotech
Groups
Investigational
Description

Rasdegafusp alfa is under investigation in clinical trial NCT03206047 (Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer).

Synonyms
Not Available
External IDs
CDX-1401
Categories
Not Available
UNII
SU9AMV39DB
CAS number
1587257-96-2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAlkylating Agent-Related Acute Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Refractory Anemia With Excess Blasts in Transformation1
1CompletedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Anaplastic Oligodendroglioma (AO) / Estrogen Receptor Negative / Estrogen Receptor Positive / Glioblastomas / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Metastatic Renal Cell Cancer / Recurrent Adult Brain Neoplasm / Recurrent Bladder Carcinoma / Recurrent Breast Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastric Carcinoma / Recurrent Hepatocellular Carcinoma / Recurrent Lung Carcinoma / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Recurrent Prostate Carcinoma / Recurrent Uterine Corpus Carcinoma / Renal Cell Carcinoma Recurrent / Resectable Hepatocellular Carcinoma / Sarcomas / Stage IA Breast Cancer / Stage IA Ovarian Cancer / Stage IA Uterine Corpus Cancer / Stage IB Breast Cancer / Stage IB Ovarian Cancer / Stage IB Uterine Corpus Cancer / Stage IC Ovarian Cancer / Stage II Uterine Corpus Cancer / Stage IIA Breast Cancer / Stage IIA Lung Carcinoma / Stage IIA Ovarian Cancer / Stage IIB Breast Cancer / Stage IIB Esophageal Cancer / Stage IIB Lung Carcinoma / Stage IIB Ovarian Cancer / Stage IIB Skin Melanoma / Stage IIC Ovarian Cancer / Stage IIC Skin Melanoma / Stage IIIA Breast Cancer / Stage IIIA Esophageal Cancer / Stage IIIA Lung Carcinoma / Stage IIIA Ovarian Cancer / Stage IIIA Skin Melanoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Breast Cancer / Stage IIIB Esophageal Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Skin Melanoma / Stage IIIB Uterine Corpus Cancer / Stage IIIC Breast Cancer / Stage IIIC Esophageal Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Skin Melanoma / Stage IIIC Uterine Corpus Cancer / Stage IV Bladder Urothelial Carcinoma / Stage IV Esophageal Cancer / Stage IV Ovarian Cancer / Stage IV Prostate Cancer / Stage IV Skin Melanoma / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
1RecruitingTreatmentBlasts 30 Percent or Less of Bone Marrow Nucleated Cells / Chronic Myelomonocytic Leukemia / High Risk Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Refractory Anemia1
1, 2CompletedTreatmentAdvanced Malignancies1
1, 2RecruitingTreatmentFallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Carcinoma1
1, 2SuspendedTreatmentPlatinum-Resistant Fallopian Tube Carcinoma / Platinum-Resistant Ovarian Carcinoma / Platinum-Resistant Primary Peritoneal Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
1, 2WithdrawnTreatmentAdvanced Triple Negative Breast Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Melanoma / Mesothelioma / Urothelial Cancer1
2SuspendedTreatmentCarcinoma of Unknown Primary Origin / Cutaneous Melanoma / Iris Melanoma / Medium/Large Size Posterior Uveal Melanoma / Mucosal Melanoma / NY-ESO-1 Positive Tumor Cells Present / Ocular Melanoma / Ocular Melanoma With Extraocular Extension / Small Size Posterior Uveal Melanoma / Stage IIB Cutaneous Melanoma AJCC v6 and v7 / Stage IIB Skin Melanoma / Stage IIB Uveal Melanoma / Stage IIC Cutaneous Melanoma AJCC v6 and v7 / Stage IIC Skin Melanoma / Stage III Cutaneous Melanoma AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIA Skin Melanoma / Stage IIIA Uveal Melanoma / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Skin Melanoma / Stage IIIB Uveal Melanoma / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Skin Melanoma / Stage IIIC Uveal Melanoma / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Skin Melanoma / Stage IV Uveal Melanoma1
2WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:57 / Updated on May 21, 2019 12:37